Ann: paxalisib PNOC collaboration, page-12

Given they are already doing DIPG this seems like maybe its casting doubt on the continuation of that into phase II as a mono therapy.

It kind of says that its part it may be part of a solution but in combination only.

Yep Cantrixil I thought was bad news or really no news the only new thing was the 3 years survival of one patient and it went up and this one is on the path and the SP sits a little. Yes the market is firmly chaos efficiency may is more like an underlying factor.